Can Dipeptidyl Peptidase 4 Inhibitor Be the Therapeutic Candidate for the COVID-19?
Abstract
N/A
J Endocrinol Metab. 2020;10(2):35-35
doi: https://doi.org/10.14740/jem641
J Endocrinol Metab. 2020;10(2):35-35
doi: https://doi.org/10.14740/jem641
User
|
MOST READ |
(For the last 6-month published articles)
Article Tools
Email this article (Login required)
Email this article (Login required) |
QUICK LINKS |
|
|
|
|
|
|
Submit Manuscript |
|
|
Editorial Board |
|
|
|
|
|
|
|
|
|
|
|
Conflict of Interest |
|
|
|
|
|
|
|
|
|
|
ARTICLE STATISTICS |
|
Submission to First Decision |
|
25 Days |
|
Acceptance Rate |
|
37% |
|
Acceptance to Publication |
|
38 Days |
|
*Average article statistics from the last 12 months data |